News

CXCR2 blockers stop cancer
Enlarge image

ResearchGermanyUK

CXCR2 blockers stop cancer

30.08.2012 - Formation of tumours can be significantly reduced by inhibition of a receptor that drives inflammation, according to a British-German research team.

According to the scientists headed by Robert Nibbs from Biomedical Research Centre Glasgow, inhibition of the chemokine receptor CXCR2 „profoundly suppressed inflammation-driven tumourigenesis in models for skin and intestinal cancers as well as in adenomas“ (JCI, doi: 1172/JCI61067). Either chemical blocking of CXCR2 or knock-out of the receptor gene prevented proinflammatory chemokines, which were selectively expressed in adenomas, skin and intestinal tumours, to bind to the receptor. CXCR2 deficiency inhibited recruitment of neutrophils and tumour-associated leukocytes, according to the authors from Glasgow and their partners from Ludwig-Maximilians University Munich.

Chronic inflammation is found frequently in the development of a number of benign and malignant cancers, particularly in colorectal cancers where ulcerative colitis increases the risk of developing colon cancer 20-fold. Treatment of patients with ulcerative colitis with anti-inflammatory compounds can reduce their cancer risk by 50%. Thus, the researchers believe that CRCX2 blockers may be attractive therapeutic targets to prevent and treat inflammation-driven cancers.

http://www.european-biotechnology-news.com/news/news/2012-03/inflammation-blockers-stop-cancer.html

Stock marketsEU

29.01.2015 Denmark's Ascendis Pharma has successfully raised US$108m with its upsized NASDAQ IPO, while Irish animal health specialist Nexvet is waiting in the wings.

Contract ResearchEU

28.01.2015 EMA recommends suspending around 750 generic medicines marketed throughout the world after India’s GVK Biosciences is accused of faking bioequivalence studies. Meds considered critically important for patients will remain available.

RegulationEU

21.01.2015 The EMA is asking for comments on how to implement the transparency rules of EU Clinical Trial Regulation, pointing to the new clinical trial portal and database as the main instrument.

Stock marketsEUGermany

21.01.2015 2014 was a record year for biotech companies on the European stock market, with a total of €2.4bn raised in the year - 25% more than in the year before.

ResearchEUUK

20.01.2015 Ebola research projects are set to receive €215m in funding from the European Commission’s IMI2 Ebola+ programme. Among the project partners are vaccine developers Glaxosmithkline, Johnson&Johnson and Merck. 

Stock ExchangeUKDenmarkFrance

16.01.2015 It's time to get used to weekly IPO plans by European biotechs. UK's drug discovery firm Redx Pharma Ltd, established just five years ago, has come of age with their £80m (€105m) IPO plans.

M&ASwitzerland

14.01.2015 Pharma kingpin Roche has launched a billion-dollar transaction for a total of US$1.2bn (€1bn), taking over the majority of US cancer specialist Foundation Medicine.

PoliticsEU

14.01.2015 The European Parliament has backed the legislation allowing individual countries to restrict or prohibit the cultivation of genetically modified crops that have been authorised at EU level.

M&AIrelandUK

13.01.2015 Shire beefs up its rare disease portfolio after acquiring NPS Pharma with the aim of becoming a leading biotech in a US$5.2bn deal. Part of the deal is the US biotech's lead portfolio of gastrointestinal and hormone replacement therapies.

M&ASwitzerlandFrance

09.01.2015 The excitement surrounding CRISPR genome editing shows no sign of abating. This month, Novartis and US biotech Intellia Therapeutics became the first ever biotech-pharma collaboration to use the groundbreaking technology.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • CO.DON2.40 EUR11.63%
  • SARTORIUS113.95 EUR4.93%
  • EVONIK27.85 EUR3.69%

FLOP

  • ADDEX3.30 CHF-4.07%
  • BIOFRONTERA1.95 EUR-3.47%
  • MEDIGENE3.70 EUR-2.63%

TOP

  • CYTOS0.33 CHF43.5%
  • ADDEX3.30 CHF42.2%
  • FORMYCON14.30 EUR41.9%

FLOP

  • BIOFRONTERA1.95 EUR-15.2%
  • ACTELION100.20 CHF-13.8%
  • MOLOGEN5.60 EUR-11.8%

TOP

  • SANTHERA105.50 CHF2570.9%
  • WILEX1.96 EUR168.5%
  • BB BIOTECH256.75 EUR98.6%

FLOP

  • CYTOS0.33 CHF-90.9%
  • MOLOGEN5.60 EUR-51.0%
  • 4SC0.82 EUR-50.9%

No liability assumed, Date: 29.01.2015